Mike Bio: Announcement on providing guarantee for the company’s dealers to apply for credit lines from banks
Securities code: 300463 Securities abbreviation: Mike Biotechnology Announcement number: 2025-085
Mike Biotechnology Co., Ltd.
Announcement on providing guarantee for the company's dealers to apply for credit lines from banks
The company and all members of the board of directors guarantee that the contents of the announcement are true, accurate and complete, and that there are no false records, misleading statements or major omissions.
Important content reminder:
Name of the guaranteed party: The registered distributors of Mike Biotechnology Co., Ltd. (hereinafter referred to as "Company" or "Mike Biotechnology") and its subsidiaries who meet certain conditions. There is no related relationship between the guaranteed party and the company, and there is no related guarantee. Whether there is a counter-guarantee for this guarantee: The dealer needs to provide Mike Biotech with a counter-guarantee equal to the guarantee amount. The counter-guarantee can be in the form of real estate mortgage, chattel pledge, joint guarantee by family members, etc. that are agreed upon by both parties.
The cumulative number of overdue external guarantees: there are no overdue external guarantees, no external guarantees involving litigation, and situations where the guarantee should bear losses due to the judgment of losing the lawsuit.
1. Overview of guarantee situation
(1) The company’s current cumulative guarantees for dealers
As of the date of this announcement, the company’s actual guarantee balance for dealers is RMB 169.0 million. The details are as follows: Main Contractor As of now Whether
Guarantee contract Guarantee validity period Guarantee
Serial number Same debt Secured party Guarantee balance Corresponding loan term Related
Signing date to type
Rights holder (10,000 yuan) Guarantee Chengdu Huize
August 2024 August 2025 October 10, 2024 to Joint and several liability
1 Biotechnology 3,000 No. 27th 8th October 2025 Ren Bao
Ltd.
Prosperity
From January 10, 2025 to Jointly and severally liable
Bank Chengdu Xike 1,700 No
June 2024 June 2025 January 9, 2026 Ren Bao
2 shares Rui Technology has
June 26, 2025 June 6, 2025 to June 6, 2025 Jointly and severally liable
Limited company 2,000 No
June 5, 2026 Ren Bao
company
Chengdu Haoying
Chengdu December 2024 November 2025 December 5, 2024 to Jointly and severally liable
3 Like Technology has 2,700 branches No. 4 March 21 December 4, 2025 Any guarantee
Ltd.
November 22, 2024 to
4 Chengdu Maibang 1,100 August 2024 August 2025 Joint and several liability No November 21, 2025
Page 1 of 15 Securities code: 300463 Securities abbreviation: Mike Biotechnology Announcement number: 2025-085
Source Biology Department From October 27th to 8th, Ren Guaranty will be from October 10th to 2024.
Technology Co., Ltd. 1,600
October 9, 2025
Division
Chengdu Orun
Kang Biotechnology June 2024 January 2025 October 31, 2024 to Joint and several liability 5 3,800 Fu Technology Co., Ltd. October 26 3 October 30, 2025 Ren Guaranty Department
Chengdu Angel
Special medical devices March 2024 March 2025 March 20, 2025 to Joint and several liability 6 1,000 Fu Medical Equipment Co., Ltd. March 27 March 20 March 19, 2026 Ren Guaranty Department
Total 16,900 - - - - -
The above-mentioned guarantees provided by Mike Biotech to dealers have been reviewed and approved by the company at the 19th meeting of the fifth board of directors and the 17th meeting of the fifth board of supervisors held on October 11, 2024, and at the second extraordinary general meeting of shareholders of 2024 held on October 28, 2024. The guarantee is valid for one year from the review and approval of the general meeting of shareholders.
(2) The company provides guarantees for dealers to apply for credit lines from banks.
In view of the fact that the validity period of the above guarantee is coming to an end, in order to continue to support the operations of dealers, in order to continue to support the operations of dealers, on September 29, 2025, the sixth meeting of the sixth board of directors and the sixth meeting of the sixth board of supervisors of Mike Biotechnology respectively reviewed and approved the "Proposal on Providing Guarantees for the Company's Dealers to Apply for Credit Lines from Banks" and agreed to provide qualified dealers with designated services under the premise that the risks are controllable.
Banks applying for a credit limit of no more than RMB 350 million will provide joint liability guarantees. The above proposal still needs to be submitted to the company's third extraordinary general meeting of shareholders in 2025 for review, and the guarantee limit for dealers will take effect from the date of review and approval by the general meeting of shareholders.
2. Estimated amount of external guarantees
This new guarantee amount accounts for
Guaranteed Party Secured Party Up to now
Increased post-guarantee Is the listed company related to the guarantor? The guaranteed party’s shareholding ratio. Assets in the most recent period. Guarantee balance.
Insured amount Returned to the parent in the most recent period Guarantee example Liability ratio (10,000 yuan)
(10,000 yuan) Net assets ratio
Chengdu Huize Biological Sciences
0 73% 3,000 5,000 0.79% Fu Technology Co., Ltd.
Chengdu Xikerui Technology
0 77% 3,700 2,400 0.38% No limited company
Chengdu Yintai Biological Sciences
Mike Biotech 0 83% 0 4,000 0.63% Fouji Co., Ltd.
Limited by Shares
Chengdu Haoying Technology
Company 0 86% 2,700 2,600 0.41% No limited company
Chengdu Maibanyuan Biology
0 89% 2,700 3,000 0.47% Fou Technology Co., Ltd.
Sichuan Zhenghongkang Medical
0 83% 0 2,000 0.31% No Instrument Co., Ltd.
Page 2 of 15 Securities code: 300463 Securities abbreviation: Mike Biotechnology Announcement number: 2025-085
Chengdu Orunkang Biology
0 86% 3,800 3,200 0.50% Fou Technology Co., Ltd.
Chengdu Shengyuanxin Medical
0 73% 0 2,000 0.31% No Equipment Co., Ltd.
Chengdu Angel Medical
0 75% 1,000 1,000 0.16% No Equipment Co., Ltd.
Potential guaranteed person - - 0 9,800 1.54% No
Total - - 16,900 35,000 5.50% -
3. Basic information of the guaranteed person
(1) Chengdu Huize Biotechnology Co., Ltd.
Name of the guaranteed party: Chengdu Huize Biotechnology Co., Ltd.
Date of establishment: November 7, 2013
Registered capital: 1 million yuan
Registered address: No. 2, 3rd Floor, Building 1, No. 189, Wuke West 2nd Road, Wuhou District, Chengdu City, No. 307 and 308
Legal representative: Chen Siyu
Business scope: Licensed items: wholesale of medicines; operation of Class III medical devices; leasing of Class III medical devices. (Projects that require approval according to law can only be carried out with the approval of relevant departments. Specific business projects are subject to the approval documents or licenses of relevant departments) General projects: technical services, technology development, technical consultation, technology exchange, technology transfer, technology promotion; software development; second-class medical device leasing; first-class medical treatment Equipment leasing; repair of special equipment; wholesale of protective equipment for medical staff; sales of Class II medical devices; sales of Class I medical devices; sales of instruments and meters; sales of industrial automatic control system devices; wholesale of computer software, hardware and auxiliary equipment; wholesale of hardware products; leasing services (excluding licensed leasing services); import and export of goods. (Except for projects that require approval according to law, business activities can be carried out independently with a business license and in accordance with the law)
Relationship between the guaranteed person and the company: no related relationship
Main financial indicators:
Unit: Yuan Project December 31, 2024 (audited) June 30, 2025 (unaudited) Total assets 193,387,239.80 163,296,961.65 Total liabilities 141,347,104.38 108,516,842.57 Including: total bank loans 70,000,000.00 49,500,000.00
Page 3 of 15 Securities code: 300463 Securities abbreviation: Mike Biotechnology Announcement number: 2025-085
Total current liabilities 141,347,104.38 108,516,842.57 Asset-liability ratio 73% 66% Total owners’ equity 52,040,135.42 54,780,119.08
Item 2024 (audited) Operating income from January to June 2025 (unaudited) 164,855,714.88 51,962,398.45 Total profit 12,585,472.43 4,091,775.42 Net profit 9,404,671.51 3,068,802.80 Note: The above-mentioned financial data of the secured party in 2024 has been audited, and the financial data from January to June 2025 has not been audited.
The guaranteed party is not a person subject to execution for breach of trust.
(2) Chengdu Xikerui Technology Co., Ltd.
Name of the guaranteed party: Chengdu Xikerui Technology Co., Ltd.
Date of establishment: November 15, 2013
Registered capital: 2 million yuan
Registered address: Area B, first floor, Southwest Trunk Line Transportation Building, No. 78 Wukexi 1st Road, Wuhou E-commerce Industrial Functional Zone Management Committee, Wuhou District, Chengdu City
Legal representative: Liu Jie
Business scope: Licensed items: wholesale of medicines; leasing of Class III medical devices; operation of Class III medical devices. (Projects that require approval according to law can only be carried out with the approval of relevant departments. Specific business projects are subject to the approval documents or licenses of relevant departments.) General projects: software development; technical services, technology development, technical consultation, technology exchange, technology transfer, technology promotion; second-class medical device leasing; second-class medical device sales; first-class medical device sales; first-class medical device leasing; experimental analysis instrument sales; special equipment repair. (Except for projects that require approval according to law, business activities can be carried out independently with a business license and in accordance with the law)
Relationship between the guaranteed person and the company: no related relationship
Main financial indicators:
Unit: Yuan
Project December 31, 2024 (audited) June 30, 2025 (unaudited) Total assets 95,370,755.93 69,520,722.22 Total liabilities 73,436,949.90 50,831,259.08
Page 4 of 15 Securities code: 300463 Securities abbreviation: Mike Biotechnology Announcement number: 2025-085
Including: Total bank loans 54,000,000.00 42,000,000.00
Total current liabilities 73,436,949.90 50,831,259.08 Asset-liability ratio 77% 73% Total owners’ equity 21,933,806.03 18,689,463.14
Item 2024 (audited) Operating income from January to June 2025 (unaudited) 88,942,795.23 21,806,164.74 Total profit 3,077,712.80 797,516.31 Net profit 2,372,826.60 598,137.23 Note: The above-mentioned financial data of the secured party in 2024 has been audited, but the financial data from January to June 2025 has not been audited.
The guaranteed party is not a person subject to execution for breach of trust.
(3) Chengdu Yintai Biotechnology Co., Ltd.
Name of the guaranteed person: Chengdu Yintai Biotechnology Co., Ltd.
Date of establishment: January 2, 2014
Registered capital: 1 million yuan
Registered address: Room 301, Floor 3, Building 1, No. 189, Wuke West 2nd Road, Wuhou District, Chengdu City
Legal representative: Meishidian
Business scope: Licensed items: Category III medical device operation; Category III medical device leasing; pharmaceutical wholesale. (Projects that require approval according to law can only be carried out with the approval of relevant departments. Specific business projects are subject to the approval documents or licenses of relevant departments) General projects: technical services, technology development, technical consultation, technology exchange, technology transfer, technology promotion; sales of second-class medical devices; leasing of second-class medical devices; first-class projects Sales of medical devices; leasing of Class I medical devices; wholesale of medical masks; retail of protective equipment for medical staff; repair of special equipment; retail of computer software, hardware and auxiliary equipment; sales of instruments and meters; sales of electrical accessories; sales of special electronic equipment; sales of mechanical equipment; conference and exhibition services; sales of office supplies; sales of paper products. (Except for projects that require approval according to law, business activities can be carried out independently with a business license and in accordance with the law)
Relationship between the guaranteed person and the company: no related relationship
Main financial indicators:
Unit: Yuan
Project December 31, 2024 (audited) June 30, 2025 (unaudited) Total assets 135,414,459.69 131,438,840.27
Page 5 of 15 Securities code: 300463 Securities abbreviation: Mike Biotechnology Announcement number: 2025-085
Total liabilities 112,937,620.97 105,645,990.21 Including: Total bank loans 60,000,000.00 60,000,000.00 Total current liabilities 112,937,620.97 105,645,990.21 Asset-liability ratio 83% 80% Total owners’ equity 22,476,838.72 25,792,850.06 Project 2024 (audited) January-June 2025 (unaudited) operating income 152,569,946.27 63,954,434.47 Total profit 10,005,227.34 4,585,589.19 Net profit 7,595,114.30 3,316,011.34 Note: The above-mentioned secured party’s financial data for 2024 has been audited, but the financial data from January to June 2025 has not been audited.
The guaranteed party is not a person subject to execution for breach of trust.
(4) Chengdu Haoying Technology Co., Ltd.
Name of the guaranteed person: Chengdu Haoying Technology Co., Ltd.
Date of establishment: August 23, 2012
Registered capital: 2 million yuan
Registered address: No. 410, No. 1, 4th Floor, Building 1, No. 189, Wuke West 2nd Road, Wuhou District, Chengdu City
Legal representative: Zhao Xiulan
Business scope: Licensed items: operation of Class III medical devices; wholesale of medicines; leasing of Class III medical devices. (Projects that require approval according to law can only be carried out with the approval of relevant departments. Specific business projects are subject to the approval documents or licenses of relevant departments) General projects: software development; technical services, technology development, technical consultation, technology exchange, technology transfer, technology promotion; retail of computer software, hardware and auxiliary equipment; sales of first-class medical devices; sales of second-class medical devices; sales of building materials; daily necessities Sales; sales of electronic products; sales of power electronic components; sales of cameras and equipment; retail of sporting goods and equipment; operation of wires and cables; sales of household appliances; sales of chemical products (excluding licensed chemical products); sales of office supplies; retail of clothing and apparel; retail of cosmetics; leasing services (excluding licensed leasing services); leasing of Class II medical devices; leasing of Class I medical devices; leasing of machinery and equipment. (Except for projects that require approval according to law, business activities can be carried out independently with a business license and in accordance with the law)
Relationship between the guaranteed person and the company: no related relationship
Main financial indicators:
Page 6 of 15 Securities code: 300463 Securities abbreviation: Mike Biotechnology Announcement number: 2025-085
Unit: Yuan
Project December 31, 2024 (audited) June 30, 2025 (unaudited) Total assets 116,964,631.18 87,377,290.63 Total liabilities 100,282,092.99 72,228,981.08 Including: Total bank loans 45,000,000.00 45,000,000.00
Total current liabilities 100,282,092.99 72,228,981.08 Asset-liability ratio 86% 83% Total owners’ equity 16,682,538.19 15,148,309.55
Project 2024 (audited) Operating income from January to June 2025 (unaudited) 77,329,128.86 24,957,199.95Total profit 3,140,667.20 -1,226,480.42Net profit 2,355,500.40 -1,226,480.42 Note: The above-mentioned financial data of the secured party in 2024 has been audited, and the financial data from January to June 2025 has not been audited.
The guaranteed party is not a person subject to execution for breach of trust.
(5) Chengdu Maibonyuan Biotechnology Co., Ltd.
Name of the guaranteed party: Chengdu Maibonyuan Biotechnology Co., Ltd.
Date of establishment: November 22, 2013
Registered capital: 1 million yuan
Registered address: No. 505, Floor 1, Building 1, No. 189, Wuke West 2nd Road, Wuhou District, Chengdu City
Legal representative: Li Guiming
Business scope: Licensed items: wholesale of medicines; leasing of Class III medical devices; operation of Class III medical devices. (Projects that require approval according to law can only be carried out with the approval of relevant departments. Specific business projects are subject to the approval documents or licenses of relevant departments) General projects: technical services, technology development, technical consultation, technology exchange, technology transfer, technology promotion; Class I medical device leasing; Class I medical devices Machinery sales; Class II medical device leasing; Class II medical device sales; Retail sale of computer software, hardware and auxiliary equipment; Wholesale of computer software, hardware and auxiliary equipment; General mechanical equipment installation services; Sales of office supplies; Sales of electronic products; Sales of chemical products (excluding licensed chemical products); Repair of special equipment. (Except for projects that require approval according to law, business activities can be carried out independently with a business license and in accordance with the law)
Relationship between the guaranteed person and the company: no related relationship
Page 7 of 15 Securities code: 300463 Securities abbreviation: Mike Biotechnology Announcement number: 2025-085
- Main financial indicators:
Unit: Yuan
Project December 31, 2024 (audited) June 30, 2025 (unaudited) Total assets 122,725,611.12 96,702,585.02 Total liabilities 109,788,618.27 84,217,845.62 Including: Total bank loans 45,000,000.00 48,000,000.00
Total current liabilities 109,788,618.27 84,217,845.62 Asset-liability ratio 89% 87% Total owners’ equity 12,936,992.85 12,484,739.40
Project 2024 (audited) Operating income from January to June 2025 (unaudited) 104,549,179.40 29,196,808.66 Total profit 5,443,168.81 1,284,565.32 Net profit 4,082,376.61 963,423.99 Note: The above-mentioned secured party’s financial data for 2024 has been audited, but the financial data from January to June 2025 has not been audited.
The guaranteed party is not a person subject to execution for breach of trust.
(6) Sichuan Zhenghongkang Medical Instrument Co., Ltd.
Name of the guaranteed party: Sichuan Zhenghongkang Medical Instrument Co., Ltd.
Date of establishment: March 24, 2014
Registered capital: 2 million yuan
Registered address: No. 502, Floor 1, Building 1, No. 189, Wuke West 2nd Road, Wuhou District, Chengdu City
Legal representative: Su Zuqin
Business scope: Licensed items: Operation of Class III medical devices; Leasing of Class III medical devices; Wholesale of pharmaceuticals (items subject to approval according to law can only be carried out after approval by relevant departments. Specific business items are subject to approval documents or licenses from relevant departments). General items: sales of sanitary products and disposable medical supplies; sales of experimental analysis instruments; Secondary Sales of Class 1 medical devices; repair of special equipment; sales of Class 1 medical devices; leasing of Class 2 medical devices; leasing of Class 1 medical devices; technical services, technology development, technical consultation, technology exchange, technology transfer, and technology promotion; sales of special chemical products (excluding hazardous chemicals) (except for projects that require approval in accordance with the law, independently carry out business activities with a business license in accordance with the law)
Relationship between the guaranteed person and the company: no related relationship
Page 8 of 15 Securities code: 300463 Securities abbreviation: Mike Biotechnology Announcement number: 2025-085
- Main financial indicators:
Unit: Yuan
Project December 31, 2024 (audited) June 30, 2025 (unaudited) Total assets 120,371,766.07 103,966,604.80 Total liabilities 100,112,920.70 84,149,691.03 Including: Total bank loans 43,730,380.98 42,943,333.76
Total current liabilities 99,952,123.26 83,310,579.58 Asset-liability ratio 83% 81% Total owners’ equity 20,258,845.37 19,816,913.77
Project 2024 (audited) Operating income from January to June 2025 (unaudited) 83,210,422.77 39,538,777.83 Total profit 5,308,282.83 -2,233,505.66 Net profit 3,981,223.83 -2,233,505.66 Note: The above-mentioned financial data of the secured party in 2024 has been audited, and the financial data from January to June 2025 has not been audited.
The guaranteed party is not a person subject to execution for breach of trust.
(7) Chengdu Orunkang Biotechnology Co., Ltd.
Name of the guaranteed person: Chengdu Ourunkang Biotechnology Co., Ltd.
Date of establishment: December 19, 2017
Registered capital: 2 million yuan
Registered address: No. 1, 3rd Floor, Building 1, No. 77, Wuxing 5th Road, Wuhou District, Chengdu City, Sichuan Province
Legal representative: Li Chengguo
Business scope: Licensed items: operation of Class III medical devices; wholesale of medicines; leasing of Class III medical devices. (Projects that require approval according to law can only be carried out with the approval of relevant departments. Specific business projects are subject to the approval documents or licenses of relevant departments) General projects: technical services, technology development, technical consultation, technology exchange, technology transfer, technology promotion; sales of first-class medical devices; second-class medical devices Sales of medical devices; leasing of Class I medical devices; leasing of Class II medical devices; sales of machinery and equipment; sales of instruments and meters; retail of protective equipment for medical staff; retail of medical masks; retail of computer software, hardware and auxiliary equipment; wholesale of computer software, hardware and auxiliary equipment; conference and exhibition services; repair of special equipment. (Except for projects that require approval according to law, business activities can be carried out independently with a business license and in accordance with the law)
Page 9 of 15 Securities code: 300463 Securities abbreviation: Mike Biotechnology Announcement number: 2025-085
Relationship between the guaranteed person and the company: no related relationship
Main financial indicators:
Unit: Yuan
Project December 31, 2024 (audited) June 30, 2025 (unaudited) Total assets 139,205,112.75 127,747,920.26 Total liabilities 119,216,567.28 109,691,293.17 Including: Total bank loans 59,924,763.92 70,799,843.98
Total current liabilities 119,216,567.28 109,691,293.17 Asset-liability ratio 86% 86% Total owners’ equity 19,988,545.47 18,056,627.09
Project 2024 (audited) Operating income from January to June 2025 (unaudited) 137,338,362.25 55,683,547.84 Total profit 10,031,414.73 3,573,955.12 Net profit 8,610,043.55 2,680,466.34 Note: The above-mentioned secured party’s financial data for 2024 has been audited, but the financial data from January to June 2025 has not been audited.
The guaranteed party is not a person subject to execution for breach of trust.
(8) Chengdu Shengyuanxin Medical Equipment Co., Ltd.
Name of the guaranteed party: Chengdu Shengyuanxin Medical Equipment Co., Ltd.
Date of establishment: September 9, 2019
Registered capital: 2 million yuan
Registered address: No. 701, Floor 7, Unit 1, Building 2, No. 9, Wuxing 2nd Road, Wuhou New Town Management Committee, Wuhou District, Chengdu City
Legal representative: Gongli
Business scope: Licensed items: Category III medical device operation; Category III medical device leasing; pharmaceutical wholesale. (Projects that require approval according to law can only be carried out with the approval of relevant departments. Specific business projects are subject to the approval documents or licenses of relevant departments.) General projects: sales of Class I medical devices; leasing of Class I medical devices; sales of Class II medical devices; leasing of Class II medical devices; retail of computer software, hardware and auxiliary equipment; technical services, technology development, technical consulting, technical exchanges, technology transfer, and technology promotion. (Except for projects that require approval according to law, business activities can be carried out independently with a business license and in accordance with the law)
Page 10 of 15 Securities code: 300463 Securities abbreviation: Mike Biotechnology Announcement number: 2025-085
Relationship between the guaranteed person and the company: no related relationship
Main financial indicators:
Unit: Yuan
Project December 31, 2024 (audited) June 30, 2025 (unaudited) Total assets 72,247,933.98 45,236,682.75 Total liabilities 53,082,259.88 28,713,567.31 Including: Total bank loans 20,000,000.00 0.00
Total current liabilities 53,082,259.88 28,713,567.31 Asset-liability ratio 73% 63% Total owners’ equity 19,165,674.10 16,523,115.44
Project 2024 (audited) Operating income from January to June 2025 (unaudited) 84,387,996.87 32,355,493.94 Total profit 6,671,684.41 1,363,175.85 Net profit 5,779,888.39 1,022,381.89 Note: The above-mentioned financial data of the secured party in 2024 has been audited, and the financial data from January to June 2025 has not been audited.
The guaranteed party is not a person subject to execution for breach of trust.
(9) Chengdu Angel Medical Equipment Co., Ltd.
Name of the guaranteed party: Chengdu Angel Medical Equipment Co., Ltd.
Date of establishment: September 7, 2017
Registered capital: 1 million yuan
Registered address: Fourth Floor, No. 1, Building 17, No. 218 Jingye Road, Qingyang District, Chengdu City
Legal representative: Huang Xinyi
Business scope: Licensed items: Category III medical device operation; Category III medical device leasing; wholesale of medicines; road cargo transportation (excluding dangerous goods) (items that require approval according to law can only be carried out after approval by relevant departments. Specific business projects are subject to approval documents or licenses from relevant departments) General projects: technical services, technology development, technical consulting, Technology exchange, technology transfer, technology promotion; software development; Class II medical device leasing; Class II medical device sales; Class I medical device leasing; Class I medical device sales; special equipment repair; wholesale of protective equipment for medical staff; sales of instruments and meters; sales of industrial automatic control system devices; wholesale of computer software, hardware and auxiliary equipment; wholesale of hardware products; leasing services
Page 11 of 15 Securities code: 300463 Securities abbreviation: Mike Biotechnology Announcement number: 2025-085
(excluding licensed leasing services); import and export of goods; sales of electronic products; sales of machinery and equipment; sales of building materials; sales of chemical products (excluding licensed chemical products); sales of daily necessities; wholesale of clothing and apparel; sales of office supplies; wholesale of sporting goods and equipment; new material technology promotion services; socioeconomic consulting services services; market research (excluding foreign-related investigations); conference and exhibition services; graphic design and production; advertising design, agency; sales agency; advertising production; advertising release; small and micro bus rental and operating services; business management; marketing planning (except for projects that require approval according to law, independently carry out business activities with a business license in accordance with the law)
Relationship between the guaranteed person and the company: no related relationship
Main financial indicators:
Unit: Yuan
Project December 31, 2024 (audited) June 30, 2025 (unaudited) Total assets 48,248,127.74 50,021,640.20 Total liabilities 36,123,713.33 36,717,493.07 Including: Total bank loans 10,000,000.00 11,000,000.00
Total current liabilities 36,123,713.33 36,717,493.07 Asset-liability ratio 75% 73% Total owners’ equity 12,124,414.41 13,304,147.13
Project 2024 (audited) Operating income from January to June 2025 (unaudited) 69,378,918.51 29,811,152.43 Total profit 3,846,484.84 1,396,655.79 Net profit 2,874,339.37 1,179,732.72 Note: The above-mentioned financial data of the secured party in 2024 has been audited, but the financial data from January to June 2025 has not been audited.
The guaranteed party is not a person subject to execution for breach of trust.
(10) Potential guaranteed persons
The potential guaranteed person is a downstream non-affiliated dealer recommended by the company or its wholly-owned subsidiary and included in the scope of credit customers after review and confirmation by the bank. The company will select dealers who have a certain basis for cooperation, good business reputation, comply with the company's marketing disciplines and sales settlement system, and have future development expectations based on historical transaction records with dealers and dealer credit status to recommend them to the bank. If a dealer violates relevant laws or the agreement between the parties, the company may consider canceling the guarantee or reducing the guarantee amount.
There is no related relationship between the guaranteed party and the company, and it does not constitute related guarantee.
Page 12 of 15 Securities code: 300463 Securities abbreviation: Mike Biotechnology Announcement number: 2025-085
4. Main contents of the guarantee agreement
This guarantee has not yet signed a guarantee agreement with the relevant parties.
The main contents of the guarantee currently determined by the company include:
Guarantee method: joint liability guarantee guarantee.
Guarantee period: one year, effective upon review and approval by the shareholders’ meeting.
Guarantee amount: The total guarantee amount shall not exceed RMB 350 million. The details shall be subject to the guarantee contract signed by the bank.
Risk management and control measures for external guarantees
Regarding the matter of providing guarantees for the company's dealers to apply for credit lines from banks, the company will formulate corresponding operating specifications, clarify risk control measures, and reduce guarantee risks, mainly including the following:
(1) The company is responsible for reviewing and recommending the qualifications of dealers included in the guarantee scope to ensure that the dealers who join have good credit and good repayment ability.
(2) The dealer’s financing purpose under the guaranteed credit line is limited to payment of purchase price to the company and its wholly-owned subsidiaries. (3) The company requires dealers to provide counter-guarantees to the company. Counter-guarantees include but are not limited to property mortgages in the name of dealers or shareholders and actual controllers, chattel pledges, joint guarantees by family members, and other methods agreed upon by both parties. The company will carefully judge the enforceability of the counter-guarantee and the actual guarantee capacity of the counter-guarantee provider. After the company fulfills its guarantee responsibilities for dealers, it has the right to recover according to law within the scope of the guarantee.
(4) The company will strictly follow the relevant systems, articles of association, and agreements to conduct pre-guarantee review, in-guarantee supervision, and post-guarantee review of dealers, without damaging the rights and interests of the company and small and medium-sized shareholders.
5. Opinions of the Board of Directors
The company's board of directors believes that providing guarantees for loan credits to qualified dealers complies with the relevant provisions and requirements of the "Supervisory Guidelines for Listed Companies No. 8 - Supervisory Requirements for Capital Transactions and External Guarantees of Listed Companies" (China Securities Regulatory Commission Announcement [2022] No. 26) and the "Articles of Association".
On the premise that the overall risk is controllable, this guarantee meets the company's long-term development needs and is conducive to helping dealers solve the problem of fund shortages, expand sales, and further establish good long-term cooperative relationships with dealers. It is also conducive to the collection of accounts receivable, increasing the company's asset liquidity, and achieving a win-win situation for the company and dealers.
This guarantee does not violate the relevant regulations of the China Securities Regulatory Commission and the Articles of Association, and is in line with the company and the majority of shareholders.
Page 13 of 15 Securities code: 300463 Securities abbreviation: Mike Biotechnology Announcement number: 2025-085
interests of shareholders and will not harm the interests of the company and small and medium shareholders.
6. Opinions of independent directors
The independent directors held the fourth special meeting of the sixth session of the Board of Directors and believed that the provision of external guarantees will promote the channel business development of the company and its wholly-owned subsidiaries, help dealers solve the problem of fund shortages in operating activities, help achieve a win-win situation for the company and dealers, and is in the interests of all shareholders. In addition, in accordance with the provisions of relevant laws, regulations and normative documents such as the Company Law of the People's Republic of China, the Guarantee Law of the People's Republic of China and the Articles of Association, the approval procedures for the company's external guarantees comply with the requirements of laws, regulations and normative documents. We unanimously agree that the company will provide external guarantees this time.
7. Opinions of the Supervisory Board
The company's provision of external guarantees this time will be of great help in promoting the development of the company's channel business, helping dealers solve the problem of fund shortages in operating activities, and achieving a win-win situation between the company and dealers. Moreover, this external guarantee will not affect the normal production and operation of the company and its subsidiaries, and will not harm the interests of the company and small and medium-sized shareholders. The decision-making and review procedures for this matter are legal and compliant. In summary, the Board of Supervisors agrees with the company’s provision of external guarantees this time.
8. Cumulative number of external guarantees and number of overdue guarantees
As of the date of this announcement, the total amount of external guarantees provided by the company and its holding subsidiaries is RMB 1.15 billion (including this guarantee limit), accounting for 18.06% of the company's audited net assets as of December 31, 2024. The actual external guarantee balance of the company and its holding subsidiaries is RMB 43 , 2.0701 million yuan, accounting for 6.78% of the company's audited net assets on December 31, 2024; the company's total guarantee line for subsidiaries is 800 million yuan (excluding this guarantee line), accounting for 6.78% of the company's audited net assets on December 31, 2024 The proportion of calculated net assets is 12.56%, and the actual guarantee balance for subsidiaries is RMB 263.0701 million, accounting for 4.13% of the company's audited net assets on December 31, 2024; the total amount of the company's external guarantees (excluding guarantees for subsidiaries) is 35 ,0 million yuan (including the guarantee limit), accounting for 5.50% of the company's audited net assets on December 31, 2024, and the actual external guarantee balance is RMB 169 million, accounting for 2.65% of the company's audited net assets on December 31, 2024.
As of the date of this announcement, the company and its subsidiaries have no overdue external guarantees, no external guarantees involving litigation, and no losses due to the failure of the guarantee judgment.
9. Documents for reference
Resolution of the sixth meeting of the sixth board of directors
Resolution of the fourth special meeting of independent directors of the sixth session of the Board of Directors
Page 14 of 15 Securities code: 300463 Securities abbreviation: Mike Biotechnology Announcement number: 2025-085
- Resolution of the Sixth Meeting of the Sixth Supervisory Board
Announcement is hereby made.
Mike Biotechnology Co., Ltd.
Board of Directors September 30, 2025
Page 15 of 15